Acquisition of AMAL Therapeutics

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform  Acquisition adds key platform supporting Boehringer Ingelheim ’s focus on patients with difficult-to-treat gastrointestinal and lung cancers AMAL ’s first-in-class proprietary KISIMA® platform leverages peptide/protein-based vaccination technology AMAL will remain at the campus of the University of Geneva in Switzerland and operate as a subsidiary within Boehringer Ingelheim  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news